(2017). Combined Approach of Ligand Targeted and Stimuli-triggered Nanocarriers: a State-of-the-art Strategy for Cancer Treatment. Iranian Journal of Pharmaceutical Research, 16(2), 411-412.
. "Combined Approach of Ligand Targeted and Stimuli-triggered Nanocarriers: a State-of-the-art Strategy for Cancer Treatment". Iranian Journal of Pharmaceutical Research, 16, 2, 2017, 411-412.
(2017). 'Combined Approach of Ligand Targeted and Stimuli-triggered Nanocarriers: a State-of-the-art Strategy for Cancer Treatment', Iranian Journal of Pharmaceutical Research, 16(2), pp. 411-412.
Combined Approach of Ligand Targeted and Stimuli-triggered Nanocarriers: a State-of-the-art Strategy for Cancer Treatment. Iranian Journal of Pharmaceutical Research, 2017; 16(2): 411-412.
Combined Approach of Ligand Targeted and Stimuli-triggered Nanocarriers: a State-of-the-art Strategy for Cancer Treatment
Top